InSitu Biologics, Inc
Localized sustained-release drug delivery system for peripheral nerve blocks
- Sector
- Medtech
- Headquarters
- Oakdale, MN
- Founded
- 2017
- Latest Form D
- $4M, Dec 2025
- Total capital
- $11.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $11.9M
- 5 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 13 pending · first 2022
- Rank in peer group#425 of 1112
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$4M
- Private capital raisedForm D · SEC · 4th filing$3M
- Private capital raisedForm D · SEC · 3rd filing$5M
- Offering registeredForm D · SEC · 2nd filing$1M
- Offering registeredForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1112 peers
Line = medianMedtech · Device
- Granted patents#425 · top 38%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andy LaFrenceDirectorNamed in SEC Form D filings
- Bill TaylorExecutive OfficerNamed in SEC Form D filings
- Buzz BensonDirectorNamed in SEC Form D filings
- Daniel HalpernExecutive Officer, DirectorNamed in SEC Form D filings
- Greg Van GuilderDirectorNamed in SEC Form D filings
- Ivan ShawDirectorNamed in SEC Form D filings
Show all 14 people
- James KnappExecutive OfficerNamed in SEC Form D filings
- Jim SegermarkExecutive OfficerNamed in SEC Form D filings
- Kay WarnottExecutive OfficerNamed in SEC Form D filings
- Kevin BarrettExecutive OfficerNamed in SEC Form D filings
- Kevin BassettExecutive Officer, DirectorNamed in SEC Form D filings
- Mark ErethExecutive OfficerNamed in SEC Form D filings
- Robert WilsonDirectorNamed in SEC Form D filings
- Sandi KlemannExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 15- PendingHydrogel-based Biological Delivery VehicleUSPTOApplication 19343940
- GrantedHydrogel-based Biological Delivery VehicleUSPTOUS 12,427,105
- PendingSustained Release Stable Emulsion Pharmaceutical FormulationsUSPTOApplication 18631935
Show all 15 patent records
- Hydrogel-based Biological Delivery VehicleJan 29, 2026 · Application 19343940Pending
- Hydrogel-based Biological Delivery VehicleSep 30, 2025 · US 12,427,105Granted
- Sustained Release Stable Emulsion Pharmaceutical FormulationsOct 10, 2024 · Application 18631935Pending
- Sustained Release Cancer Therapeutics FormulationsSep 26, 2024 · Application 18615846Pending
- Sustained Release Cancer Therapeutics FormulationsAug 17, 2023 · Application 18109028Pending
- Echogenic Compositions And Methods Of Use Thereof For The Treatment Of PainApr 13, 2023 · Application 17965738Pending
- Hydrogel-based Biological Delivery VehicleOct 18, 2022 · US 11,471,402Granted
- Compositions And Methods For Sustained Treatment Of PainAug 4, 2022 · Application 17589639Pending
- Hydrogel-based Biological Delivery VehicleApplication PCTUS2017032406Pending
- Sustained Release Stable Emulsion Pharmaceutical FormulationsApplication PCTUS2024023902Pending
- Sustained Release Cancer Therapeutics FormulationsApplication PCTUS2024021353Pending
- Sustained Release Cancer Therapeutics FormulationsApplication PCTUS2023012926Pending
- Echogenic Compositions And Methods Of Use Thereof For The Treatment Of PainApplication PCTUS2022046624Pending
- Compositions And Methods For Sustained Treatment Of PainApplication PCTUS2022014625Pending
- Sustained Release Pharmaceutical FormulationsApplication 63232027Pending
Related companies, and why
- NeuroVasc Technologies, Inc.Similar federal contract value in Medtech · null in contracts
- Amplifyer Bio, Inc.Similar federal contract value in Medtech · null in contracts
- EyeNetra, Inc.Similar federal contract value in Medtech · null in contracts
- ForSight VISION6Similar federal contract value in Medtech · null in contracts
- Level Zero HealthSimilar federal contract value in Medtech · null in contracts
- Voyager Biomedical, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .